Zurzuvae: New Hope Pill for Moms with Post-Partum Depression
Sage Therapeutics, Inc. and Biogen Inc. have announced the availability of ZURZUVAE™ (zuranolone) by prescription in the United States...
FDA Nods to Padcev-Keytruda for Bladder Cancer
Pfizer Inc. and Astellas Pharma Inc. have announced the FDA’s approval of PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC])...
BMS’s RELATIVITY-123 Trial Fail: A Devastating End
Bristol Myers Squibb announced the discontinuation of the Phase 3 RELATIVITY-123 trial, which was evaluating the fixed-dose combination of...
Pfizer Seals Deal: Seagen Now Acquired for $229/Share
Pfizer Inc. has announced the completion of its acquisition of Seagen Inc., marking a significant expansion in its commitment...
Shattering Myths FDA New Era of Diverse Healthcare Solutions
In an era marked by rapid advancements in healthcare, the importance of inclusivity and innovation in clinical trials and...
Pfizer Bold 2024 Forecast: A New Era Dawns
Pfizer Inc. has provided its financial forecast guidance for the full year of 2024, accounting for the anticipated impact...
ACRO Unveils Power Squad for 2024: Meet the New Faces
The Association of Clinical Research Organizations (ACRO) announced the election of Peyton Howell, Chief Operating & Growth Officer at...
Miracle CAR T-Cell Hope from Gilead for Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), has presented encouraging data from various studies on the CAR T-cell therapies Tecartus®...
Mooresville Locals Breathe Easy with Sanofi COPD Study
A new clinical trial, known as the AERIFY-2 study, is underway in Mooresville, N.C., focusing on chronic obstructive pulmonary...
Pfizer & Seagen Merge: A Monumental, Surprising Union
Pfizer Inc. has reached a significant milestone in its pending acquisition of Seagen Inc., with all required regulatory approvals...